Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors

Koto,Kazutaka; Murata,Hiroaki; Sawai,Yasushi; Ashihara,Eishi; Horii,Motoyuki; Kubo,Toshikazu

doi:10.3892/ol.2017.6355

Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors

Authors:
- Kazutaka Koto
- Hiroaki Murata
- Yasushi Sawai
- Eishi Ashihara
- Motoyuki Horii
- Toshikazu Kubo
View Affiliations

Affiliations: Department of Orthopaedics, Meiji University of Integrative Medicine, Nantan, Kyoto 629‑0301, Japan, Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Kyoto 602‑8566, Japan, Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Kyoto, Kyoto 607‑8414, Japan
Published online on: June 8, 2017 https://doi.org/10.3892/ol.2017.6355
Pages: 1648-1656

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastatic and primary bone tumors are malignant tumors affecting the skeleton. Although the prognosis of patients with these tumors has improved with the development of effective chemotherapy, the challenges of local recurrence, subsequent osteolysis, degradation of bone strength and unresectable tumors persist. Local control of these tumors is therefore a key strategy to address these limitations. The third‑generation bisphosphonate (BP), zoledronic acid (ZOL), has been demonstrated to reduce osteoclasts and exhibited potent antitumor effects in a number of malignancies. Hydroxyapatite (HA) and polymethyl methacrylate (PMMA) bone cement are used in orthopedic surgery as bone graft substitutes, for implant arthroplasty and bone strengthening, and as a sustained‑release system for drugs such as antibiotics. At present, the antitumor effects of ZOL‑loaded HA in vitro or in vivo or of ZOL‑loaded bone cement in vivo have not been described. Therefore, the present study assessed the effects of ZOL‑loaded HA and bone cement in malignant tumor cells. The two materials exerted strong antitumor effects against osteosarcoma, fibrosarcoma, synovial sarcoma, renal cancer, prostate cancer and lung cancer cells upon releasing ZOL. The antitumor effects of ZOL‑loaded HA were less potent compared with those of ZOL‑loaded bone cement, possibly as BPs exhibit higher affinity to HA. ZOL‑loaded bone cement also exerted antitumor effects against pulmonary metastases and primary lesions, without exhibiting systemic toxicity in vivo. These results demonstrate that these materials may be beneficial for the treatment of malignant bone tumors, including metastatic bone tumors. In addition, as these materials are already in clinical use, such applications may be easily implemented.

View Figures

View References

1	Unni KK and Inwards CY: Dahlin's bone tumors, General Aspects and Data on 10,165 Cases. Lippincott Williams & Wilkins; Philadelphia, PA: pp. 3052010
2	Desai S and Jambhekar N: Clinicopathological evaluation of metastatic carcinomas of bone: A retrospective analysis of 114 cases over 10 years. Indian J Pathol Microbiol. 38:49–54. 1995.PubMed/NCBI
3	Doung YC, Kenan S and Rapp T: Metastatic lesions of the proximal femur. Bull NYU Hosp Jt Dis. 69:81–86. 2011.PubMed/NCBI
4	Weiss RJ, Forsberg JA and Wedin R: Surgery of skeletal metastases in 306 patients with prostate cancer. Acta Orthop. 83:74–79. 2012. View Article : Google Scholar : PubMed/NCBI
5	Wedin R, Bauer HC and Wersäll P: Failures after operation for skeletal metastatic lesions of long bones. Clin Orthop Relat Res. 1–139. 1999.PubMed/NCBI
6	Wedin R: Surgical treatment for pathologic fracture. Acta Orthop Scand Suppl. 72:2pp1–29. 2001. View Article : Google Scholar
7	Chien SH, Hung SH, Cheng YM, Lin GT, Lin SY, Ko CY, Chen LH and Chiang HC: Surgical treatment of pathologic fracture of the femur. Kaohsiung J Med Sci. 13:556–561. 1997.PubMed/NCBI
8	Russell RG and Rogers MJ: Bisphosphonates: From the laboratory to the clinic and back again. Bone. 25:97–106. 1999. View Article : Google Scholar : PubMed/NCBI
9	Green JR: Antitumor effects of bisphosphonates. Cancer. 97 3 Suppl:S840–S847. 2003. View Article : Google Scholar
10	Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61:2602–2608. 2001.PubMed/NCBI
11	Kubo T, Shimose S, Matsuo T, Tanaka K, Yasunaga Y, Sakai A and Ochi M: Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res. 24:1138–1144. 2006. View Article : Google Scholar : PubMed/NCBI
12	Koto K, Murata H, Kimura S, Horie N, Matsui T, Nishigaki Y, Ryu K, Sakabe T, Itoi M, Ashihara E, et al: Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep. 24:233–239. 2010.PubMed/NCBI
13	Horie N, Murata H, Nishigaki Y, Matsui T, Segawa H, Nogawa M, Yuasa T, Kimura S, Maekawa T, Fushiki S and Kubo T: The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis. Cancer Lett. 238:111–118. 2006. View Article : Google Scholar : PubMed/NCBI
14	Horie N, Murata H, Kimura S, Takeshita H, Sakabe T, Matsui T, Maekawa T, Kubo T and Fushiki S: Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer. 96:255–261. 2007. View Article : Google Scholar : PubMed/NCBI
15	Koto K, Horie N, Kimura S, Murata H, Sakabe T, Matsui T, Watanabe M, Adachi S, Maekawa T, Fushiki S and Kubo T: Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett. 274:271–278. 2009. View Article : Google Scholar : PubMed/NCBI
16	Jagdev SP, Coleman RE, Shipman CM, Rostami HA and Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer. 84:1126–1134. 2001. View Article : Google Scholar : PubMed/NCBI
17	Junqueira LC and Carneiro J: Basic Histology, Text & Atlas. 10th. MacGrow-Hill Companies; New York: pp. 1442003
18	Yamamoto T, Onga T, Marui T and Mizuno K: Use of hydroxyapatite to fill cavities after excision of benign bone tumours. J Bone Joint Surg Br. 82:1117–1120. 2000. View Article : Google Scholar : PubMed/NCBI
19	Uchida A, Araki N, Shinto Y, Yoshikawa H, Kurisaki E and Ono K: The use of calcium hydroxyapatite ceramic in bone tumour surgery. J Bone Joint Surg Br. 72:298–302. 1990.PubMed/NCBI
20	Shinto Y, Uchida A, Korkusuz F, Araki N and Ono K: Calcium hydroxyapatite ceramic used as a delivery system for antibiotics. J Bone Joint Surg Br. 74:600–604. 1992.PubMed/NCBI
21	Hirata M, Murata H, Takeshita H, Sakabe T, Tsuji Y and Kubo T: Use of purified beta-tricalcium phosphate for filling defects after curettage of benign bone tumours. Int Orthop. 30:510–513. 2006. View Article : Google Scholar : PubMed/NCBI
22	Itokazu M, Kumazawa S, Wada E and Wenyi Y: Sustained release of adriamycin from implanted hydroxyapatite blocks for the treatment of experimental osteogenic sarcoma in mice. Cancer Lett. 107:11–18. 1996. View Article : Google Scholar : PubMed/NCBI
23	Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S and Yoshikawa H: Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer. 76:418–422. 1998. View Article : Google Scholar : PubMed/NCBI
24	Fogh J, Fogh JM and Orfeo T: One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 59:221–226. 1977. View Article : Google Scholar : PubMed/NCBI
25	Rasheed S, Nelson-Rees WA, Toth EM, Arnstein P and Gardner MB: Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer. 33:1027–1033. 1974. View Article : Google Scholar : PubMed/NCBI
26	Kawai A, Naito N, Yoshida A, Morimoto Y, Ouchida M, Shimizu K and Beppu Y: Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett. 204:105–113. 2004. View Article : Google Scholar : PubMed/NCBI
27	Williams RD, Elliott AY, Stein N and Fraley EE: In vitro cultivation of human renal cell cancer. II. Characterization of cell lines. In Vitro. 14:779–786. 1978. View Article : Google Scholar : PubMed/NCBI
28	Ohnuki Y, Marnell MM, Babcock MS, Lechner JF and Kaighn ME: Chromosomal analysis of human prostatic adenocarcinoma cell lines. Cancer Res. 40:524–534. 1980.PubMed/NCBI
29	Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H and Parks WP: In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 51:1417–1423. 1973. View Article : Google Scholar : PubMed/NCBI
30	Hansen MB, Nielsen SE and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 119:203–210. 1989. View Article : Google Scholar : PubMed/NCBI
31	Euhus DM, Hudd C, LaRegina MC and Johnson FE: Tumor measurement in the nude mouse. J Surg Oncol. 31:229–234. 1986. View Article : Google Scholar : PubMed/NCBI
32	Tomayko MM and Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 24:148–154. 1989. View Article : Google Scholar : PubMed/NCBI
33	Jensen MM, Jorgensen JT, Binderup T and Kjaer A: Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging. 8:162008. View Article : Google Scholar : PubMed/NCBI
34	Zwolak P, Manivel JC, Jasinski P, Kirstein MN, Dudek AZ, Fisher J and Cheng EY: Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Joint Surg Am. 92:162–168. 2010. View Article : Google Scholar : PubMed/NCBI
35	Zhang S, Gangal G and Uludağ H: ‘Magic bullets’ for bone diseases: Progress in rational design of bone-seeking medicinal agents. Chem Soc Rev. 36:507–531. 2007. View Article : Google Scholar : PubMed/NCBI
36	Yamasaki M, Yuasa T, Uehara S, Fujii Y, Yamamoto S, Masuda H, Fukui I and Yonese J: Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab. Int J Clin Oncol. 21:1191–1195. 2016. View Article : Google Scholar : PubMed/NCBI
37	Kubo T, Shimose S, Matsuo T, Sakai A and Ochi M: Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells. Cancer Chemother Pharmacol. 62:111–116. 2008. View Article : Google Scholar : PubMed/NCBI
38	Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE and Holen I: Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 100:1167–1178. 2008. View Article : Google Scholar : PubMed/NCBI